All In Biotech

Drug Trial Radar · NCT07935343

Comparison of Topical Permethrin 5% and Spinosad 0.9% for Scabies Treatment

Comparison of the Efficacy of Topical Permethrin 5% and Spinosad 0.9% in the Treatment of Scabies: A Randomised Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
University of FaisalabadAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized controlled clinical trial is to compare the effectiveness of topical Permethrin 5% cream and Spinosad 0.9% suspension in treating scabies in patients aged 5-60 years. The main questions it aims to answer are: * Is there a difference in the effectiveness of topical Permethrin 5% and Spinosad 0.9% in treating scabies at Day 14? * What are the treatment-related adverse effects of these two medications? Researchers will compare the two treatment groups to determine whether there is a significant difference in treatment efficacy. Participants will be randomly assigned to one of two groups: * Group A will receive topical Permethrin 5% cream, applied from the neck to the toes for 8-12 hours, followed by washing. A second application will be given after 7 days. * Group B will receive topical Spinosad 0.9% suspension, applied similarly, with repeat application only if clinically indicated. Participants will be instructed regarding correct treatment application, hygiene measures, and treatment of close contacts. They will be assessed at baseline, Day 7, and Day 14. The main outcome will be treatment efficacy at Day 14, defined as complete resolution of itching, healing of skin lesions, and absence of new lesions.

Conditions

  • Scabies

Interventions

  • Permethrin 5%Drug

    Patients will receive topical Permethrin 5% cream applied from neck to toe for 8-12 hours followed by washing. A second application will be given after 7 days.

  • spinosad topical suspension, 0.9%Drug

    Patients will receive topical Spinosad 0.9% suspension. Repeat application will be performed only if clinically indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving treatment efficacy at day 14Time frame: Day 14 after treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Madina Teaching Hospital

    Faisalābad, Punjab Province, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.